RxDoctor Payments Data

Marilyn Lachman, MD

Psychiatry · Albertville, ALNPI 1528040599

Payments from drug & device makers

$2,156in general payments, 2019–2025

Across 153 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$684
  • Otsuka America Pharmaceutical, Inc.$466
  • Takeda Pharmaceuticals U.S.A., Inc.$334
  • Avanir Pharmaceuticals, Inc.$107
  • Indivior Inc.$93
  • Vanda Pharmaceuticals Inc.$78
  • plus $394 from 11 others

What the payments were for

  • Food & beverage$2,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,156 in reported general payments places this provider in the 70th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$10,950
Medicare patients
41
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl219$317,425
RexultiBrexpiprazole81$163,550
Abilify MaintenaAripiprazole49$124,321
TrintellixVortioxetine Hydrobromide153$79,448
AustedoDeutetrabenazine13$65,800
NeuproRotigotine65$54,938
Lurasidone Hcl222$51,273
BelsomraSuvorexant76$32,928
FetzimaLevomilnacipran Hcl45$24,796
Vilazodone Hcl291$22,204
CaplytaLumateperone Tosylate11$21,160
MovantikNaloxegol Oxalate35$14,465
Aripiprazole241$12,788
Alprazolam2,572$12,212
VyvanseLisdexamfetamine Dimesylate31$11,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima, Linzess, Namzaric$40$360,353294 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$466$287,871130 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$334$91,009184 claims
Teva Pharmaceuticals USA, Inc.Austedo$39$65,80013 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$74$21,16011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Albertville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →